Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Andexanet alfa versus usual care for acute intracranial hemorrhage in patients on oral factor Xa inhibitors
NL-OMON54049Phase 4Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of andexanet alfa in intracerebral hemorrhage (ICH) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Effective hemostasis at 12 hours post-randomization. Started Nov 2020; status: completed.
02
Drugs
andexanet alfa
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on NL-OMON54049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54049.